StockGuru Profile

Skinvisible Signs Global Licensing Agreement for Its Cannabis Products

Skinvisible Signs Global Licensing Agreement for Its Cannabis Products

Invisicare Enhances the Delivery of Topical Medical Marijuana in New Product Line

LAS VEGAS, NV / ACCESSWIRE / September 15, 2016 / Skinvisible Pharmaceuticals, Inc., (SKVI), developers of patented Invisicare® polymer delivery systems, announces it has licensed the exclusive world rights to its topical and transdermal cannabis products formulated with Invisicare to CannaSkin, LLC, a cannabis product licensing company with international contacts in the medical marijuana industry.

CannaSkin has the exclusive license to manufacture, market and sub-license Skinvisible’s new cannabis products. Their targets will initially include facilities in the 25 US jurisdictions currently approved for medical marijuana as well as Canada and Israel where there is a great demand for cannabis products supported by science.

Skinvisible will utilize its patented skin delivery system Invisicare to formulate and deliver high-quality topical cannabinoid products containing CBD and THC. CBD has proven to have many therapeutic effects and it does not produce the “high” associated with THC. Cannabinoids have been used to treat many skin conditions, from acne, eczema, psoriasis, skin cancer, to anti-aging, due to their anti-oxidant and anti-inflammatory properties. Skinvisible’s Invisicare technology allows for the superior binding of these products to the skin, a controlled release of the cannabinoids both topically and transdermally, as well as providing patent protection.

“We are excited to enter into the emerging global cannabis market with CannaSkin, an extremely qualified partner in the cannabis industry,” said Terry Howlett, President of Skinvisible. “Skinvisible will bring a new era of cannabis products; ones supported by science and patents. Our objective is to provide superior products with many options for medical marijuana consumers.”

There is rapid growth in the number of legalized marijuana jurisdictions in the USA and internationally and with that, revenues growing at an exponential rate. According to AcrView Market Research, legal US cannabis sales are projected to increase by 25% in 2016 to $6.7 billion.

About Skinvisible Pharmaceuticals, Inc. 

Skinvisible Pharmaceuticals is a R&D company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time along with controlling the release of actives. Kintari Int. Inc., a wholly-owned subsidiary markets its cosmeceutical and OTC products.

www.skinvisible.com
www.invisicare.com

Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending June 30, 2016).

Contact:

Doreen McMorran, Skinvisible Inc.
info@skinvisible.com
Phone: 702-433-7154

John Pentony is a consultant to Skinvisible and is currently being paid nineteen hundred dollars for a program that covers the Company through January 18, 2017. There are no shares, warrants or other equity related compensation. Mr. Pentony previously represented Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock.

Skinvisible Pharmaceuticals Inc.

OTCQB: SKVI

Skinvisible, Inc., through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is an R&D pharmaceutical company that develops enhanced, patent protected dermatology and healthcare products including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis along with sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations, and various other medical treatments using its patented technology Invisicare®.

Skinvisible's primary objective is to license these prescription and over-the-counter products into the $65 billion global dermatology market and other medical markets. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products.

DISCLOSURE: John Pentony is a consultant to Skinvisible and is currently being paid nineteen hundred dollars for a program that covers the Company through January 18, 2017. There are no shares, warrants or other equity related compensation. Mr. Pentony previously represented Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock.